Healthcare
Monday, April 18, 2016
BRIEF-Dynavax presents pivotal phase 3 data showing HEPLISAV-B provides significantly higher protection against Hepatitis B than ENGERIX-B(R)
* Dynavax presents pivotal phase 3 data showing
heplisav-b(tm) provides significantly higher protection against
hepatitis b than engerix-b(r)
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment